BioVaxys Outlines Focus on Pipeline Expansion, Clinical Advancement

On June 3, BioVaxys Technology Corp. (OTC:BVAXF) issued a comprehensive corporate update, detailing its strategic initiatives. BioVaxys is focusing on strategic initiatives, such as integrating assets acquired from IMV Inc. in February 2024, out-licensing its DPX platform, and restarting clinical studies, notably DPX-surMAGE for advanced bladder cancer. The company is also expanding its pipeline through collaborations and reducing risks by seeking co-development partners for late-stage clinical programs.

BioVaxys Outlines Focus on Pipeline Expansion, Clinical Advancement

A scientist in a biopharmaceutical laboratory examining the development of a product candidate intended to treat a central nervous system disease.

These efforts are expected to enhance BioVaxys’s market position in cancer immunotherapy. BioVaxys’s late-stage pipeline includes MVP-S, which is currently in phase 2b clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma/DLBCL and platinum-resistant ovarian cancer. Results from a phase 1b/2 study of MVP-S in combination with low-dose cyclophosphamide in patients with recurrent ovarian cancer showed that this combination was well-tolerated and generated an overall response rate of 21% and a disease control rate of 63%.

In a phase 2b study, MVP-S, plus the immunotherapy drug Keytruda (pembrolizumab), also showed promising results in the treatment of patients with relapsed/refractory DLBCL, where 3/6 patients in the study arm experienced confirmed complete responses.

BioVaxys Technology Corp. (OTC:BVAXF) is a clinical-stage biotechnology company that develops viral and oncology vaccine platforms and immuno-diagnostics.

While we acknowledge the potential of BVAXF to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BVAXF and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.